Skip to main content
SpringerLink
Log in

Famciclovir vs aciclovir - let the battle commence

  • Newsletter Article
  • Published:
Inpharma Weekly

Abstract

For the first time, Wellcome’s aciclovir faces tough competition as an antiviral treatment for herpes zoster (shingles). The competition comes in the form of SmithKline Beecham’s new drug famciclovir [Famvir®]. If its claimed advantages are seen in practice, this drug may whittle away the monopoly held by aciclovir.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Authors
  1. Robert Short
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Short, R. Famciclovir vs aciclovir - let the battle commence. Inpharma Wkly. 923, 17 (1994). https://doi.org/10.2165/00128413-199409230-00044

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128413-199409230-00044

Keywords

Search

Navigation